Latest Insider Transactions at Bio Atla, Inc. (BCAB)
This section provides a real-time view of insider transactions for Bio Atla, Inc. (BCAB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BioAtla, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BioAtla, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2021
|
Richard A Waldron Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
31,976
+16.1%
|
-
|
|
Dec 18
2020
|
Guy Levy Director |
BUY
Open market or private purchase
|
Indirect |
1,388,890
+50.0%
|
$25,000,020
$18.0 P/Share
|
|
Dec 18
2020
|
Guy Levy Director |
BUY
Conversion of derivative security
|
Indirect |
1,790,472
+50.0%
|
-
|
|
Dec 18
2020
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
800,000
+25.87%
|
$14,400,000
$18.0 P/Share
|
|
Dec 18
2020
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
1,492,060
+50.0%
|
-
|
|
Dec 18
2020
|
Pfizer Inc > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,238,090
+50.0%
|
-
|